Results 61 to 70 of about 237 (77)
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. [PDF]
Nat Rev Drug DiscovDartois V, Dick T.
europepmc +1 more source
Journal of Clinical PharmacologyAbstractDelpazolid (LCB01‐0371) is a novel oxazolidinone derivative with a good safety profile for treating gram‐positive pathogenic infections such as Mycobacterium abscessus, a highly pathogenic drug‐resistant Mycobacterium. In this study, we evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of delpazolid after 14 days of multiple oral ...
Tae Sun Shim +2 more
exaly +4 more sources
European Journal of Clinical Microbiology and Infectious DiseasesCurrent treatment options for infections caused by vancomycin-resistant (VR) Enterococcus faecium remain limited and often suboptimal. This study investigates the in vitro activity of combination therapies involving fosfomycin and oxazolidinones (linezolid, contezolid, delpazolid, and sutezolid) against five vanA and five vanB E.
Cristina Lagatolla +2 more
exaly +5 more sources
Delpazolid. Oxazolidinone antibiotic, Treatment of tuberculosis
Drugs of the Future, 2018 Gautam Kaul
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Tuberculosis Drug Discovery and Development 2019
, 2020 Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million ...
exaly +2 more sources